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Abstract
Background: Metabolic syndrome may lead to many complications, such as nonalcoholic fatty liver disease
(NAFLD). A natural and effective therapeutic agent for patients with NAFLD is urgently needed. In a previous study,
we showed that Rhodiola crenulata root extract (RCE) regulated hepatic gluconeogenesis through activation of
AMPK signaling. However, the manner in which RCE regulates hepatic lipid and glycogen metabolism remains
unclear. The current study was conducted to investigate the effects of RCE on hepatic glycogen and lipid
metabolism, as well as the mechanisms underlying such effects.
Methods: Human hepatoma HepG2 cells were treated with RCE for 6 h under high glucose conditions, after which
glycogen synthesis, lipogenesis, and relative gene expression were examined. In addition, lipogenesis-related genes
were investigated in vivo.
Results: RCE significantly increased glycogen synthesis and inhibited lipogenesis, while regulating genes related to
these processes, including glycogen synthase kinase 3β (GSK3β), glycogen synthase (GS), fatty acid synthase (FAS),
CCAAT/enhancer-binding protein (C/EBP), and sterol regulatory element-binding protein 1c (SREBP-1c). However,
the effects caused by RCE were neutralized by compound C, an AMPK antagonist. Further studies showed that
expression levels of lipogenic genes decreased at the protein and mRNA levels in the rat liver.
Conclusions: Our results demonstrate that RCE regulates hepatic glycogen and lipid metabolism through the
AMPK signaling pathway. These results suggest that RCE is a potential intervention for patients with NAFLD.
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Background
Modern lifestyles have resulted in a sharp increase in the
occurrence of metabolic syndrome in recent decades. Meta-
bolic syndrome is primarily caused by insulin resistance
and associated with obesity and central fat distribution [1].
In addition, metabolic disorder may subsequently develop
into cardiovascular disease and type II diabetes mellitus [2].
Thus, it has become a major public health concern in de-
veloped nations [3]. Insulin resistance contributes to exces-
sive concentrations of free glucose and fatty acids in the
circulatory system, which may cause increased oxidative
stress, release of inflammatory cytokines, impaired β-
oxidation of free fatty acids, and abnormal metabolism [4].
Among the effects of insulin resistance, abnormal hepatic
glucose and lipid metabolism are the major causes of meta-
bolic syndrome. One of the consequences of insulin resist-
ance is redirection of excess glucose to de novo lipogenesis
instead of glycogen synthesis in the liver [5]. Increased de
novo lipogenesis leads to fat accumulation in the liver and
is linked to the pathological progression of cirrhosis, nonal-
coholic fatty liver disease (NAFLD), hepatitis, and liver can-
cer [6]. Thus, reduction of excessive hepatic lipidosis is an
urgent concern for patients with metabolic syndrome.
Enhanced lipogenesis and decreased glycogen synthesis
are hallmarks of hepatic insulin-resistance, which might
subsequently lead to the development of type II diabetes
mellitus [7]. The liver is the primary organ responsible for
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glycogen and lipid metabolism. Biosynthesis of glycogen
and lipids is the primary means by which the body stores
excess nutrients and is strictly controlled by a complex
network of hormones and metabolic signals. Under nor-
mal conditions, glycogen is the primary storage form of
excess energy. Glycogen production is regulated primarily
via enzymes critically involved in glycogen metabolism,
including glycogen synthase kinase 3β (GSK3β) and glyco-
gen synthase (GS) [8]. However, insulin resistance shifts
the major form of energy storage from glycogen to triglyc-
erides (TG) in the liver [9], consistent with reduced GS ac-
tivity in patients with type II diabetes [10]. These shifts in
energy storage mechanisms increase lipogenesis, enhance
cholesterol synthesis, and decrease fatty acid β-oxidation;
eventually, such effects may lead to lipotoxicity-induced
pancreatic β-cell dysfunction and metabolic syndrome [11].
5′ AMP-activated protein kinase (AMPK) coordinates
many different signaling pathways involved in mainten-
ance of energy homeostasis. AMPK is the switch control-
ling activation of anabolic and catabolic pathways [12].
AMPK regulates lipid metabolism by inactivating acetyl-
CoA carboxylase (ACC) and 3-hydroxy-3-methylglutaryl-
CoA reductase, resulting in increased lipid oxidation and
inhibited cholesterol synthesis [13]. Thus, AMPK activa-
tion in the liver suppresses gluconeogenesis, lipogenesis,
and cholesterol synthesis. Based upon its function, many
studies have suggested that AMPK might be a therapeutic
target for treatments for patients with insulin resistance
and type II diabetes mellitus [12, 14, 15].
Rhodiola crenulata has been used in the traditional
Chinese medicine system as a treatment for high altitude
illness and diabetes, as well as in tonics [16, 17]. R. crenu-
lata root extract (RCE) was recently shown to attenuate
abnormal lipid metabolism and improve insulin sensitivity
in a rodent model of diabetes [18]. In a previous study
[19], we showed that RCE suppressed hepatic gluconeo-
genesis via activation of AMPK signaling. Our results also
imply that RCE might suppress hepatic lipogenesis by in-
activating key enzymes involved in lipogenesis, including
fatty acid synthase (FAS) and ACC [20]. Although these
results indicate that RCE is able to ameliorate abnormal
glucose and lipid metabolism, the underlying mechanism
of RCE requires further elucidation. The goal of the
current study is to examine the effects of RCE on hepatic
glycogen and lipid metabolism in human HepG2 cells and
Sprague–Dawley (SD) rats, as well as to investigate the
mechanisms underlying such effects.
Methods
Preparation and quantification of RCE
Preparation and analysis of RCE were described in a
previous study by our group [19]. Briefly, Rhodiola
crenulata (Hook. f. & Thomson) H. Ohba roots were
obtained from Chuang Song Zong Pharmaceutical
Co., Ltd (Kaohsiung,Taiwan). A voucher specimen
(NDMCP no.1000901) was deposited in the National
Defense Medical Center. The identity of R. crenulata
was confirmed using the Plant List database. The
drug-extract ratio of RCE was 6.25:1. HPLC showed
that the RCE contained 3.5 % salidroside.
Cell culture and animal experiments
Human HepG2 cells [21] were purchased from the
American Type Culture Collection (ATCC, Manassas,
VA, USA) and maintained in DMEM medium (Gibco
Laboratories, Grand Island, NY, USA). Male SD rats
were employed in this study as described in a previous
study by our group [19]. Briefly, cells were treated with
different concentrations of RCE under high glucose con-
ditions (33 mM) for 16 h. SD rats were fed RCE (50 mg/
kg, suspended in 1 mL saline) or 1 mL saline by gavage
once daily for 3 days, after which the animals were sacri-
ficed and livers were collected. All of these procedures
were proven by the Institutional Animal Care and Use
Committee of the National Defense Medical Center
(IACUC-11-055).
Glycogen synthesis assay
The glycogen synthesis assay was performed as de-
scribed in a previous study [22]. Briefly, the assay was
carried out with 5.5 mM glucose (2 μCi/mL, [14C]-D-
glucose) for 30 min at 37 °C, followed by lysis with
0.5 N NaOH and measurement of the radiation intensity
of glycogen via scintillation counting (Packard).
Lipogenesis assay
The lipogenesis assay in HepG2 cells was performed using
a commercial kit (Cayman Chemical Co.) [23]. Briefly,
cells were cultured in 24-well plates, after which 75 μL of
Oil Red O solution was added to each well for 15 min.
Subsequently, dye extraction solution was added to each
well for 20 min. Finally, the absorbance of the solution in
each well was measured at 490 nm using an ELISA micro-
plate reader (Spectra Max 190, Molecular Devices).
Quantitative analysis of lipid metabolic gene expression
Relative gene expression levels of lipogenic enzymes
were measured by quantitative real-time PCR (Q-PCR)
as described previously [19]. The PCR primers are listed
in Table 1.
Western blotting
Western blotting was performed as described in a previ-
ous study by our group [24]. Briefly, immunoblotting
was performed using antibodies against AKT, phosphor-
ylated AKT (Thr308 and Ser473, Santa Cruz, CA),
CCAAT/enhancer-binding protein (C/EBP), AMPK,
phosphorylated AMPK (T172), ACC, phosphorylated
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ACC (Cell Signaling Tech.), GSK3β, phosphorylated
GSK3β (Abcam, Cambridge, MA), GS, phosphorylated
GS (Ser641), β-actin (Chemicon, Temecula, CA, USA),
and sterol regulatory element-binding protein 1c
(SREBP-1c) (Gene Tex, Irvine, CA).
Statistical analysis
All results are presented as mean ± SEM. Significant dif-
ferences between group means were determined using
one-way ANOVA followed by Bonferroni’s post-hoc test.
Analyses were performed using IBM SPSS Statistics ver-
sion 22 (IBM® SPSS® Statistics 22). Differences were con-
sidered to be statistically significant when p-values were
less than 0.05.
Results
RCE significantly increases AMPK and ACC
phosphorylation
To clarify the regulatory effect of RCE on AMPK signaling
in the liver, HepG2 cells were incubated with RCE. RCE
significantly increased AMPK phosphorylation at T172
(1.51 ± 0.19, 1.73 ± 0.14, 1.73 ± 0.17, and 1.64 ± 0.25-fold
over the control sample for 1.5, 3.0, 15.0, and 30.0 μg/mL,
respectively; p < 0.05, p < 0.001, p < 0.01, and p < 0.05, re-
spectively; Fig. 1a and b). ACC, a major substrate of
AMPK, is involved in modulating hepatic lipogenesis,
which suppresses conversion of acetyl-CoA to malonyl-
CoA and subsequently leads to decreased fatty acid syn-
thesis [25]. ACC phosphorylation following RCE treat-
ment was concentration-dependent (1.31 ± 0.12, 1.76 ±
0.32, 1.65 ± 0.12, and 1.54 ± 0.11-fold over the control
sample for 1.5, 3.0, 15.0, and 30.0 μg/mL, respectively; p <
0.05, p < 0.05, p < 0.001, and p < 0.001, respectively; Fig. 1a
and c). These results indicate that pretreatment with RCE
significantly increased the activity of the AMPK-ACC
signaling pathway in HepG2 Cells without cytotoxicity
under the chosen experimental conditions [19].
RCE enhances de novo glycogen synthesis and expression
of regulatory enzymes
To investigate the impact of RCE on glycogen synthesis,
HepG2 cells were preincubated with RCE for 6 h. As
shown in Fig. 2a, RCE at concentrations of 1.5, 3.0, 15.0,
and 30.0 μg/mL significantly increased hepatic glycogen
synthesis under high glucose conditions (1.14 ± 0.02,
1.37 ± 0.02, 1.40 ± 0.08, and 1.33 ± 0.02-fold over the
control sample, respectively; p < 0.05, p < 0.001, p < 0.01,
and p < 0.001, respectively, Fig. 2a). In addition, RCE at
concentrations of 1.5, 3.0, 15.0, and 30.0 μg/mL signifi-
cantly enhanced the expression of p-GSK3β (1.06 ± 0.15,
1.48 ± 0.10, 1.72 ± 0.29, 2.36 ± 0.31-fold over the control
sample, respectively; NS, p < 0.01, p < 0.05, and p < 0.01,
respectively; Fig. 2b and c, respectively) and p- GS (0.98
± 0.12, 1.06 ± 0.09, 1.30 ± 0.08, and 1.47 ± 0.09-fold over
the control sample, respectively; NS, NS, p < 0.01, and p
< 0.001, respectively; Fig. 2b and d, respectively). These
results indicate that RCE increased glycogen synthesis
and expression of regulatory enzymes in HepG2 cells
under high glucose conditions.
RCE reduces lipogenesis and related gene expression
In addition to the impact of RCE on hepatic glycogen syn-
thesis, the effect of RCE treatment on hepatic lipid metab-
olism was also examined. RCE at concentrations of 1.5,
3.0, 15.0, and 30.0 μg/mL significantly suppressed hepatic
lipogenesis (0.90 ± 0.04, 0.79 ± 0.04, 0.57 ± 0.05, and 0.54
± 0.05-fold, respectively; NS, p < 0.01, p < 0.001, and p <
0.001, respectively, compared to that of the control group;
Fig. 3a). Consistently, we also observed that protein levels
of C/EBP (1.02 ± 0.03, 0.98 ± 0.11, 0.64 ± 0.09, and 0.39 ±
0.09-fold for 1.5, 3.0, 15.0, and 30.0 μg/mL, respectively;
NS, NS, p < 0.01, and p < 0.001, respectively, compared to
that of the control group; Fig. 3b and c) and SREBP-1c
(0.81 ± 0.07, 0.70 ± 0.08, 0.59 ± 0.07, and 0.57 ± 0.01-fold
for 1.5, 3.0, 15.0 and 30.0 μg/mL, respectively; p < 0.05, p
< 0.05, p < 0.01, and p < 0.001, respectively, compared to
that of the control group; Fig. 3b and d) were significantly
suppressed. Furthermore, RCE treatment also suppressed
mRNA levels of lipogenesis-associated, including FAS, the
key enzyme involved in fatty acid synthesis (0.67 ± 0.11,
0.60 ± 0.09, 0.33 ± 0.04, and 0.32 ± 0.05-fold for 1.5, 3.0,
15.0, and 30.0 μg/mL, respectively; NS, p < 0.05, p < 0.001,
and p < 0.001, respectively, compared to that of the con-
trol group, Fig. 3e), and SREBP1c (0.78 ± 0.08, 0.74 ± 0.03,
0.64 ± 0.05, and 0.58 ± 0.07-fold for 1.5, 3.0, 15.0, and 30.0
μg/mL, respectively; p < 0.05, p < 0.001, p < 0.001, and p <
0.001, respectively, compared to that of the control group;
Fig. 3f). These results indicate that RCE suppressed fat ac-
cumulation in hepatic cells under high glucose conditions.
Table 1 Oligonucleotide sequences used in this study
HepG2 cells Nucleotide sequences (5′-3′) Reference















GAPDH sense AACGGCACAGTCAAGGCTGA [37]
GAPDH antisense ACGCCAGTAGACTCCACGACAT
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As a positive control, AICAR reduced protein levels of C/
EBP (0.77 ± 0.11-fold over the control sample; NS; Fig. 3b
and c) and SREBP (0.59 ± 0.02-fold over the control sam-
ple; p < 0.01; Fig. 3b and d), as well as gene expression of
FAS (0.53 ± 0.12-fold over the control sample; p < 0.01;
Fig. 3d) and SREBP1c (0.71 ± 0.06-fold over the control
sample; p < 0.01; Fig. 3e).
Compound C abolishes the effects of RCE on hepatic
glycogenesis and lipogenesis
In order to investigate the mechanism underlying the ef-
fects of RCE, compound C and LY294002 were employed.
RCE-induced glycogen biosynthesis was diminished upon
inhibition of signaling by AMPK (from 1.31 ± 0.04 to 0.89
± 0.04-fold compared with the control sample; p < 0.001;
Fig. 4a) and PI3K (from 1.31 ± 0.04 to 0.83 ± 0.05-fold
compared with the control sample; p < 0.001; Fig. 4a). In
addition, the inhibitory effect of RCE on lipogenesis was
nearly abolished by compound C (from 0.69 ± 0.07 to
0.93 ± 0.05-fold compared with the control sample; p <
0.05; Fig. 4b). However, no significant effect of LY294002
treatment was detected (from 0.69 ± 0.07 to 0.70 ± 0.05-
fold compared with the control sample; NS; Fig. 4b). Simi-
larly, compound C abolished the effects of RCE on p-ACC
Fig. 1 Effect of RCE on phosphorylation of AMPK and ACC in HepG2 cells.HepG2 cells were incubated in high-glucose medium (33 mM) for 16 h
prior to the addition of the indicated concentrations of RCE or AICAR (2 mM). After pretreatment with RCE (μg/mL) for 6 h or AICAR for 2 h,
p-AMPK and p-ACC expression levels were analyzed by western blotting (a). A quantitative analysis of the relative levels of p-AMPK (b) and p-ACC
(c) was conducted. The results represent the mean ± SEM (n = 3), ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001 vs. the sample without RCE
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(from 1.47 ± 0.09 to 0.51 ± 0.03-fold compared with the
control group; p < 0.001; Fig. 4c and d), SREBP1c (from
0.80 ± 0.01 to 0.99 ± 0.04-fold compared with the control
group; p < 0.05; Fig. 4c and e), and p-GSK3ß (from 1.35 ±
0.08 to 0.94 ± 0.02-fold compared with the control group;
p < 0.01; Fig. 4c and f). This result indicates that the regu-
latory effects of RCE on hepatic glycogen and lipid metab-
olism are associated with the AMPK signaling pathway.
RCE administration suppresses lipogenesis-related gene
expression in the rat liver
To assess the effects of RCE treatment in vivo, a ro-
dent model was employed. Hepatic C/EBP and
SREBP1c protein levels (0.24 ± 0.07 and 0.72 ± 0.08-
fold compared to the control group; p < 0.05, respect-
ively; Fig. 5a, b, and c) were significantly decreased in
the RCE-treated animals. Similarly, mRNA levels of
lipogenesis-related genes FAS and SREBP1c in the rat
liver were also suppressed by RCE treatment (0.55 ±
0.06 and 0.26 ± 0.02-fold compared to the control
group; p < 0.01 and p < 0.001, respectively; Fig. 5d and
e). These results indicate that the in vivo effects of
RCE are similar to its in vitro effects.
Discussion
The liver is an important organ for whole-body energy
homeostasis because of its regulation of glucose and
lipid metabolism [12]. Hepatic AMPK activation sup-
presses anabolic metabolism, including cholesterol and
fatty acid synthesis, and increases fatty acid oxidation by
regulating gene expression and downstream enzymatic
activities. Thus, hepatic AMPK activation is commonly
regarded as a strategy for managing metabolic syndrome
[12] and related symptoms, such as fatty liver. In a previ-
ous study, we showed that RCE increased hepatic AMPK
activation [19]. In this study, RCE significantly increased
AMPK activation and regulated glycogen synthesis and
lipogenesis in hepatic cells. The hypolipidemic effect of
RCE was verified by the decreased expression levels of
genes involved in fatty acid biosynthesis (SREBP-1c, C/
EBP, and FAS) and increased fatty acid β-oxidation
(phosphorylation of ACC) in HepG2 cells. In addition,
RCE inhibited protein and gene expression of
lipogenesis-related genes (SREBP-1c, C/EBP, and FAS) in
the rat liver. These results suggest that RCE regulates
hepatic glycogen and lipid metabolism via the AMPK
pathway (Fig. 6).
Biosynthesis of glycogen is decreased in hepatocytes
under high glucose conditions [26] and patients with
insulin resistance [27]. Impaired glucose metabolism is
associated with hepatic lipid accumulation. However,
most studies have focused on improving abnormal
lipid metabolism rather than glycogen synthesis. In
this study, we simulated hepatic insulin-resistant con-
ditions by incubating HepG2 cells in 33 mM high-
glucose medium. Pretreatment with RCE significantly
increased glycogen synthesis under high glucose con-
ditions (Fig. 2a). The effect of RCE is similar to that of
thiazolidinedione, a clinical antidiabetic drug that
Fig. 2 Effects of RCE on glycogen synthesis in HepG2 cells. HepG2
cells were cultured in 24-well plates and exposed to medium with-
out serum for 24 h. The cells were then incubated with RCE (μg/mL)
for 6 h or insulin (Ins, 100 nM) for 1 h before 14C (U)-D-glucose was
added. The intensity of 14C in glycogen was analyzed (a). Expression
levels of p-GSK3ß and p-GS were analyzed by western blotting (b). A
quantitative analysis of the relative levels of p-GSK3ß (c) and p-GS
(d) was conducted. The results represent the mean ± SEM (n = 3),
∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 vs. the sample without RCE
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increases hepatic glycogen content in diabetic rodents
[28]. In addition, we showed that RCE significantly in-
creased GSK3β phosphorylation at Ser9, thereby inhi-
biting its activity, which subsequently increased GS
activity and glycogen biosynthesis in HepG2 cells
(Fig. 2b, c, and d). These results indicate that RCE
exerted a beneficial effect on hepatic glycogen metab-
olism under high glucose conditions. Although the
PI3K/AKT signaling pathway is crucial in the
regulation of glycogen biosynthesis [7], RCE treatment
did not promote phosphorylation of AKT at T308 or
S473 in our previous study [19]. These results are thus
consistent with the effect of metformin, an AMPK ac-
tivator, as an inhibitor of Akt phosphorylation under
high glucose conditions [29]. Thus, improvement of
glycogen synthesis by RCE is not dependent on the
PI3K/AKT signaling pathway. In fact, phosphorylation
of GSK3ß was also directly regulated by AMPK
Fig. 3 Effects of RCE on TG content and expression of lipogenic enzymes in HepG2 cells. HepG2 cells were cultured in high-glucose (33 mM)
medium containing Ins (100 nM) with or without the indicated concentration of RCE (μg/mL) or AICAR (2 mM). Lipogenesis (a), relative protein
levels SREBP1and C/EBP (b), and gene expression (e and f) were measured. A quantitative analysis of the protein levels of SREBP1 (c) and C/EBP
(d) was conducted. The results represent the mean ± SEM (n = 3), ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 vs. the sample without RCE
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activation [30]. Based on these results, we suggest that
RCE might increase glycogen synthesis via the AMPK-
GSK3β -GS pathway, despite the fact that the physio-
logical significance of such an effect is still unclear.
Furthermore, a previous study mentioned that regula-
tion of GSK3 activity in pancreatic beta cells enhanced
cell viability and proliferation, an effect that would
benefit patients with type I and II diabetes [31]. The
possibility that RCE improves insulin sensitivity par-
tially via the AMPK-GSK3 pathway in pancreatic beta
cells requires further investigation.
The pathological mechanism of NAFLD is excessive lipid
accumulation in the liver due to imbalanced fatty acid syn-
thesis and oxidation [32], which are orchestrated by the
interaction of multiple factors, including SREBP-1, an im-
portant transcriptional modulator involved in hepatic lipid
metabolism that is involved in transcriptional regulation of
lipogenic enzymes (FAS and ACC), regulation of fatty acid
biosynthesis and VLDL assembly, and intracellular fatty
acid trafficking [27, 33]. In addition, overexpression of hep-
atic SREBP-1 was shown to be associated with hyperlipid-
emia in rodent models of obesity and type II diabetes [12].
Fig. 4 Effects of LY294002 (LY) and compound C (CC) on glycogen synthesis and TG content in HepG2 cells. HepG2 cells were incubated in high-
glucose medium (33 mM) for 16 h and then pretreated with RCE for 12 h or kinase inhibitors (20 μM LY294002 or 10 μM compound C) prior to
RCE treatment (15 μg/mL) for 1 h. Glycogen synthesis (a) and TG content (b) were measured. Expression levels of p-ACC, SREBP1c, and p-GSK3ß
were measured by western blotting (c). A quantitative analysis of the protein levels of p-ACC (d), SREBP1c (e), and p-GSK3ß (f) was conducted.
The results represent the mean ± SEM (n = 3). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 vs. the sample without RCE; #p < 0.05, ## p < 0.01, and
###p < 0.001 vs. the RCE-treated sample
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Here, we showed that RCE treatment significantly sup-
pressed in vitro and in vivo SREBP-1c expression. In
addition, SREBP1 expression was inhibited by AMPK acti-
vation [34]. Thus, we suggest that RCE regulated hepatic
lipid accumulation, at least partially by suppression of
SREBP-1c expression. Similarly, we found that RCE signifi-
cantly increased hepatic AMPK activation, while it phos-
phorylated and inactivated downstream substrates of
AMPK, including ACC and FAS. Phosphorylation of ACC
suppressed conversion of acetyl-CoA to malonyl-CoA,
which contributed to inhibited lipid synthesis, increased
mitochondrial fatty acid oxidation, and insulin-sensitization
[25]. This result suggests that the insulin-sensitizing effect
of RCE might have been a result of activation of the
AMPK-ACC signaling pathway. RCE exerted beneficial
effects by inhibiting fat accumulation and promoting fat
oxidation in the liver, suggesting that it might be a potential
preventive agent for NAFLD.
Glycogen metabolism is crucial for long-term physical
performance. We demonstrated that RCE improved
glycogen metabolism, which implies that RCE could en-
hance the physical performance of diabetic patients. A
recent study indicated that activation of AMPK by an
herbal medicine produced beneficial effects in a rodent
model of ethanol-induced hepatosteatosis [35]. Metfor-
min, an AMPK activator, alleviated hepatic steatosis in
obese mice [36]. With the capacity to activate AMPK,
further studies are required to elucidate whether RCE
can ameliorate hepatic steatosis in alcoholic patients. In
humans, obesity and plasma TG concentration are
Fig. 5 Effects of RCE on lipogenic protein and gene expression in rat liver. Protein (a) and gene (d and e) expression levels of C/EBP and SREBP-
1c were analyzed by western blotting and Q-PCR, respectively. A quantitative analysis of the protein levels of C/EBP (b) and SREBP-1c (c) was
conducted. The results represent the mean ± SEM (n = 3). ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001 vs. the sample without RCE
Lin et al. BMC Complementary and Alternative Medicine  (2016) 16:127 Page 8 of 10
significantly associated with the TG level in the liver
[37]. Wang et al. indicated that RCE decreased the
plasma concentration of TG in a rodent model [18].
Lee et al. indicated that RCE exerted antiadipogenic
effects involved in endogenous antioxidant enzyme re-
sponse and proline-mediated pentose phosphate path-
way in differentiated adipocytes [38]. We showed that
RCE decreased TG content in HepG2 cells. Taken to-
gether, these results suggest that RCE might be useful for
the management of systemic lipid metabolism.
Conclusion
In this study, we demonstrated the ability of RCE to
regulate glycogen and lipid metabolism in the liver. Our
results suggest that R. crenulata might be a potential
therapeutic agent for NAFLD.
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